Nov 30 2014
Monte Jade Forum (Jan. 2015): Breakthrough Treatment Options for Diverse Types of Cancer Patients with Immune-oncology Approaches
- Event Date: Thursday, January 8, 2015
- Time: 6:30PM-9:00PM
- Location: ITRI Int’l, 2870 Zanker Rd., Suite #140, San Jose, CA 95134
- Moderator and Panelists:
Roxanne Duan, Director, External Collaborations, MedImmune, LLC. (Moderator)
Cheng Liu, CEO of Eureka Therapeutics, Inc.
Sonny Hsiao, CEO of Adheren, Inc.
John C. Lin, VP, Experimental Medicine & Cancer Immunotherapy, Pfizer, Inc.
- Registration: Please register in advance. Click here.
- Member & Student $10, Non-Member$20, extra $5 for site registration
- Contact Info: email@example.com
- Light refreshments and drink will be provided.
This panel discussion will focus on the recent breakthrough treatment options, namely “immune-oncology” approaches, for a variety of cancer. The moderator will give a general introduction of the immmuno-oncology approaches and a few examples of amazingly cancer patient responses, as high as response rate in the 90% range, to immune-oncology therapies. A panel of internationally renowned researchers, clinicians and entrepreneurs will be available to discuss current clinical trials, potential issues, and investment opportunities in immune-oncology therapies for different cancer, as well as hosting a Question & Answer session at the end.
Speakers and Moderator Bio:
Dr. Roxanne Duan joined MedImmune in 2012 as Director of External Collaborations. She spearheads external collaborations with academia, government and non-profit organizations and champions the formation of the Brazilian Science without Borders postdoc program at MedI. Before joining MedImmune, Roxanne was Director of External Discovery at GSK China with the goal to bring in assets from academic laboratories. Prior to GSK China, she was VP for R&D at Adlyfe, Inc., working on diagnostic methods and therapeutics for Alzheimer’s disease. Before Adlyfe, Roxanne was VP of R&D at Functional Genetics, Inc. where she led team to the invention and development of broad-spectrum antiviral therapeutics against human targets. Prior to Functional Genetics, Roxanne was a Project Leader at Human Genome Sciences, Inc. She discovered protein drugs from gene sequences and led teams to develop them, resulting in the filing of three protein drug INDs. Roxanne has a Ph.D. degree in Pharmaceutical Chemistry from University of California, San Francisco, did postdoctoral fellowships in tumor suppressor genes at the NIH and in growth factor signalling at HHMI, had extensive experiences in protein and antibody drug discovery. She also took on roles in the Advisory Board of Women in Bio and the head of Chinese Biopharmaceutical Association. Roxanne holds more than 30 original publications, 82 published patents and 26 allowed patents.
Dr. Cheng Liu is the founder and CEO of Eureka Therapeutics, a California biotech company dedicated to antibody research and discovery for cancer immunotherapy. Prior to founding Eureka, Dr. Liu was a Principal Scientist in antibody drug discovery at Chiron (now Novartis), where he championed anti-CSF1 antibody program for treatment of bone metastasis to human clinical trials. He is the inventor of multiple issued US patents in drug discovery. In 2007, he was awarded Special US Congressional Recognition for his contributions to improving human health.. Dr. Liu received his B.S. in Cell Biology and Genetics from Beijing University and a Ph.D. in Molecular Cell Biology from the University of California, Berkeley.
John C. Lin
Dr. John C. Lin is currently Vice President, Experimental Medicine & Cancer Immunotherapy at Pfizer Inc. John has worked at a biotech startup Rinat since 2002, through its acquisition by Pfizer in 2006. Before that he was a postdoctoral fellow at Genentech Inc. from 1999-2001. He obtained a Ph.D. in Biological and Biomedical Sciences from Harvard Medical School in 1998, and his M.D. from the College of Medicine of National Taiwan University in 1992.
John is dedicated to developing novel immunotherapeutic agents to address the key mechanisms of serious human diseases. He investigated beta amyloid peptide’s impact on the age-related macular degeneration and Alzheimer’s disease. He conceived of the original idea of passive immunotherapy targeting PCSK9 for LDL lowering in 2006. His team also unveiled the critical roles of the cytokine interleukin 7 in the pathogenesis of multiple sclerosis and type 1 diabetes.
In 2013 his research responsibility has expanded into leading the overall strategy of cancer immunology in Pfizer, including checkpoint inhibitors, co-stimulators and CAR T cell therapy. For instance, he is responsible for establishing Pfizer’s collaboration with MD Anderson Cancer Center’s Immunotherapy Platform (Jan 2014), collaboration with Cellectis on CAR-T technology (Jun 2014) and collaboration with Kyowa H. Kirin on 4-1BB / CCR4 combination therapy in solid tumors (Sep 2014).
Dr. Sonny Hsiao is CEO of Adheren, Inc. He manages R&D projects in the development of immunotherapies based on cell-conjugated antibodies for cancer. He also leads the development of a novel technology platform that uses chemical methods to conjugate any therapeutic moiety onto solid surfaces such as silicon, glass or living cells. As a young PI, Sonny is currently managing a NCI-IMAT R33 grant and several collaborations with academic laboratories, including David Schaffer lab at UC Berkeley, Zev Gartner lab at UCSF, Stuart Martin lab at U of Maryland, and Monica Hinds lab at OHSU. Sonny obtained his Ph.D. degree in Chemistry and Chembio from UC Berkeley.